טוען...
Dornase alfa for cystic fibrosis
BACKGROUND: Dornase alfa is currently used as a mucolytic to treat pulmonary disease (the major cause of morbidity and mortality) in cystic fibrosis. It reduces mucus viscosity in the lungs, promoting improved clearance of secretions. This is an update of a previously published review. OBJECTIVES: T...
שמור ב:
| הוצא לאור ב: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley & Sons, Ltd
2018
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6513278/ https://ncbi.nlm.nih.gov/pubmed/30187450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD001127.pub4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|